Flatiron Health Partners with Massive Bio to Strengthen Patient Identification and Services
In a strategic move poised to reshape the landscape of oncology clinical research, Flatiron Health, a leading health technology company dedicated to transforming clinical trials through the integration of real-world data and technology, has announced a new partnership with Massive Bio, a global leader in artificial intelligence (AI)-driven clinical trial matching. The collaboration is aimed at expanding patient identification capabilities, accelerating trial enrollment timelines, and improving access to potentially life-saving therapies for cancer patients across the United States.
This partnership brings together two organizations with complementary missions and technologies. Flatiron Health, a pioneer in applying real-world evidence and data-driven solutions to clinical research, is joining forces with Massive Bio, whose cutting-edge AI algorithms and patient engagement platform have become instrumental in simplifying and personalizing the trial matching process. Together, they aim to close the gap between patients in need of innovative treatments and the clinical trials that can offer them those options.
Strategic Use of AI and Real-World Data for Enhanced Recruitment
The core of the partnership revolves around the strategic use of Massive Bio’s AI-powered patient matching system and Flatiron’s extensive network of oncology research sites. Massive Bio’s platform will be deployed on a per-study basis, allowing access to a rich and diverse database of U.S.-based cancer patients. This will help identify individuals who may not currently be participating in clinical trials but are geographically located near research sites affiliated with Flatiron. These patients will be referred for onboarding and screening at these Flatiron-partnered locations, where they can be considered for enrollment using Flatiron’s proprietary technologies and centralized patient identification services.
This integrated approach is expected to significantly reduce recruitment bottlenecks that often hinder clinical trial progress. Clinical trials in oncology, in particular, have long suffered from under-enrollment, patient ineligibility, and geographic disparities in trial site locations. The result is often costly delays in drug development and, more importantly, missed opportunities for patients to access promising new therapies.
Driving Equity in Access to Oncology Research
One of the most powerful outcomes of this collaboration lies in its potential to address persistent inequities in clinical trial access. Many underserved and rural populations are often excluded from participation due to distance from major academic medical centers or a lack of awareness about available studies. Through the integration of data from Massive Bio’s platform, patients from a wider geographic range can be identified and guided to nearby Flatiron-affiliated research sites.
Flatiron’s ability to onboard patients into its network and conduct centralized patient identification assessments ensures that promising leads are not lost due to administrative or logistical barriers. This creates a more inclusive research environment and supports the overarching goal of increasing the representation of real-world populations in clinical trials—an essential step for improving both the generalizability and equity of trial outcomes.
Enhancing Operational Efficiency and Site Support
In addition to improving patient matching and outreach, this partnership enhances operational efficiency for clinical trial sponsors and research sites. Flatiron’s technology suite offers robust tools for data capture, trial operations, and workflow optimization. When paired with Massive Bio’s AI-driven insights and patient navigation capabilities, research sites are better equipped to manage the increasing complexity of modern clinical studies.
The oncology research ecosystem has grown increasingly fragmented, with decentralized trial designs, growing protocol complexity, and rising pressure to demonstrate value and real-world effectiveness. This collaboration tackles those challenges head-on by providing a more connected, data-rich infrastructure that supports seamless patient identification and trial execution.
Flatiron’s role as a hub for research activity—alongside its strong relationships with community oncology practices and academic medical centers—ensures that sponsor trials receive consistent, high-quality data and timely patient enrollment. The company’s focus on improving site workflows aligns with Massive Bio’s strengths in patient outreach and engagement, creating a synergistic effect that benefits all stakeholders in the clinical trial ecosystem.
Reinforcing a Shared Commitment to Innovation
The partnership between Flatiron Health and Massive Bio is not a standalone initiative, but part of a broader push to modernize the clinical research paradigm. Flatiron has consistently invested in tools and collaborations that allow research to be embedded into routine clinical care. This approach reduces the burden on providers while enabling patients to access investigational therapies in the same environments where they receive standard-of-care treatment.
Massive Bio, meanwhile, has emerged as a key enabler of digital transformation in clinical research. Its AI-driven platform continuously scans for eligibility across thousands of clinical trial protocols, dynamically matching patient profiles to active studies. By integrating these capabilities into Flatiron’s expansive research infrastructure, the two companies are poised to deliver scalable, repeatable solutions that can be applied across multiple tumor types, trial phases, and sponsor portfolios.
This partnership represents a shared vision: one where trial enrollment is no longer a barrier to innovation, and where every eligible patient, regardless of location or background, has a fair opportunity to participate in cutting-edge research.
As cancer care becomes increasingly personalized and data-driven, collaborations like the one between Flatiron Health and Massive Bio are essential to closing the gap between innovation and patient access. The integration of real-world data, artificial intelligence, and scalable patient identification services has the potential to accelerate drug development, enhance diversity in trial participation, and improve outcomes across the board.
With the combined strengths of two pioneering organizations, this initiative marks an important milestone in reshaping how clinical trials are conducted—making them more efficient, more inclusive, and ultimately, more impactful for patients.
